- In June 2024, Nicotine patches are widely used in nicotine replacement therapy (NRT) to help individuals quit smoking by reducing dependence on cigarettes. Studies indicate that using a nicotine patch can increase the chances of quitting successfully by 50% to 60%. The patch delivers a steady amount of nicotine through the skin, helping to manage withdrawal symptoms while avoiding the harmful effects of smoking. By triggering dopamine release, it mimics the brain’s response to smoking, making the transition easier
- In November 2023, the University of Warwick developed a testosterone patch for postmenopausal women, aiming to provide an effective and convenient treatment for menopause-related health issues. The patch, created by Warwick’s spin-out company Medherant, utilizes transdermal TEPI technology to deliver testosterone steadily, addressing symptoms such as low libido and hormonal imbalance. Currently undergoing clinical trials, the patch is expected to be the first approved transdermal testosterone treatment for women
- In July 2023, Industria Macchine Automatiche S.P.A. (IMA) acquired Phoenix Italia S.r.l., completing the purchase of 60% of Phoenix Italia and 100% of its subsidiary Phoenix Tech S.r.l., both based in Bareggio, Milano. Additionally, IMA acquired 70% of Mespic S.r.l. and 100% of its Illinois-based subsidiary, Mespic North America Corporation, from Holding FGLG S.r.l
- In April 2023, MIT researchers developed a wearable patch that enables painless drug delivery through the skin using ultrasonic waves. This technology creates tiny channels in the skin’s outer layer, allowing medications to pass through efficiently. The patch has potential applications for treating skin conditions and can be adapted for muscle relaxants, hormones, and other drugs. Designed for comfort and precision, it offers a needle-free alternative to traditional drug delivery methods
